Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:3309809rdf:typepubmed:Citationlld:pubmed
pubmed-article:3309809lifeskim:mentionsumls-concept:C0021289lld:lifeskim
pubmed-article:3309809lifeskim:mentionsumls-concept:C0001554lld:lifeskim
pubmed-article:3309809lifeskim:mentionsumls-concept:C0031327lld:lifeskim
pubmed-article:3309809lifeskim:mentionsumls-concept:C0016610lld:lifeskim
pubmed-article:3309809lifeskim:mentionsumls-concept:C1513371lld:lifeskim
pubmed-article:3309809pubmed:issue5 Pt 2lld:pubmed
pubmed-article:3309809pubmed:dateCreated1987-11-19lld:pubmed
pubmed-article:3309809pubmed:abstractTextIn newborn, fosfomycin-cefotaxime in combination is more and more commonly used for the treatment of nosocomial infections. A pharmacokinetic study was conducted in ten newborns in the aim of suggesting a therapeutic schedule of the fosfomycin. Each newborn received 200 mg/kg, intravenously twice a day. Two groups have been formed according to the time of perfusion: 2 h or 30 min. The study of pharmacokinetic parameters do not demonstrated significant difference between the two populations. In addition, residual serum concentrations, twelve hours after the administration, are greater than the minimal inhibitory concentrations of most common pathogens causing nosocomial infections in neonates.lld:pubmed
pubmed-article:3309809pubmed:languagefrelld:pubmed
pubmed-article:3309809pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3309809pubmed:citationSubsetIMlld:pubmed
pubmed-article:3309809pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3309809pubmed:statusMEDLINElld:pubmed
pubmed-article:3309809pubmed:monthJunlld:pubmed
pubmed-article:3309809pubmed:issn0369-8114lld:pubmed
pubmed-article:3309809pubmed:authorpubmed-author:DehanMMlld:pubmed
pubmed-article:3309809pubmed:authorpubmed-author:LebrunLLlld:pubmed
pubmed-article:3309809pubmed:authorpubmed-author:MagnyJ FJFlld:pubmed
pubmed-article:3309809pubmed:authorpubmed-author:GuibertMMlld:pubmed
pubmed-article:3309809pubmed:authorpubmed-author:PoudenxFFlld:pubmed
pubmed-article:3309809pubmed:issnTypePrintlld:pubmed
pubmed-article:3309809pubmed:volume35lld:pubmed
pubmed-article:3309809pubmed:ownerNLMlld:pubmed
pubmed-article:3309809pubmed:authorsCompleteYlld:pubmed
pubmed-article:3309809pubmed:pagination750-2lld:pubmed
pubmed-article:3309809pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:3309809pubmed:meshHeadingpubmed-meshheading:3309809-...lld:pubmed
pubmed-article:3309809pubmed:meshHeadingpubmed-meshheading:3309809-...lld:pubmed
pubmed-article:3309809pubmed:meshHeadingpubmed-meshheading:3309809-...lld:pubmed
pubmed-article:3309809pubmed:meshHeadingpubmed-meshheading:3309809-...lld:pubmed
pubmed-article:3309809pubmed:meshHeadingpubmed-meshheading:3309809-...lld:pubmed
pubmed-article:3309809pubmed:meshHeadingpubmed-meshheading:3309809-...lld:pubmed
pubmed-article:3309809pubmed:meshHeadingpubmed-meshheading:3309809-...lld:pubmed
pubmed-article:3309809pubmed:meshHeadingpubmed-meshheading:3309809-...lld:pubmed
pubmed-article:3309809pubmed:year1987lld:pubmed
pubmed-article:3309809pubmed:articleTitle[Comparative pharmacokinetics of fosfomycin in the neonate: 2 modes of administration].lld:pubmed
pubmed-article:3309809pubmed:affiliationLaboratoire de Bactériologie, Hôpital Antoine-Béclère, Clamart.lld:pubmed
pubmed-article:3309809pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:3309809pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:3309809pubmed:publicationTypeEnglish Abstractlld:pubmed